公开(公告)号：US20190062401A1

公开(公告)日：2019-02-28

申请号：US16165121

申请日：2018-10-19

Applicant: Immatics Biotechnologies GmbH

Inventor： Annika SONNTAG ,  Toni WEINSCHENK ,  Andrea MAHR ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  G06F19/20 ,  C12N5/0783 ,  A61K38/17 ,  A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  A61K35/17 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: C07K14/70539 ,  A61K35/17 ,  A61K38/04 ,  A61K38/1709 ,  A61K39/0011 ,  A61K2039/5158 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55561 ,  A61K2039/55588 ,  A61P35/00 ,  A61P37/04 ,  C07K7/06 ,  C07K14/7051 ,  C07K16/2833 ,  C12N5/0636 ,  C12N5/0638 ,  C12N15/115 ,  C12N2310/16 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/574 ,  G01N33/57484 ,  G01N2333/70539 ,  G16B25/00

Abstract: A method of treating a patient who has melanoma includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has melanoma. A method of treating a patient who has melanoma includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the melanoma.

公开(公告)号：US20190055302A1

公开(公告)日：2019-02-21

申请号：US16178674

申请日：2018-11-02

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C12N15/115 ,  A61K39/00 ,  G01N33/574 ,  C12Q1/6881 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/47 ,  A61K38/00 ,  A61K35/12

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190023762A1

公开(公告)日：2019-01-24

申请号：US16152122

申请日：2018-10-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni Weinschenk ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh ,  Lea Stevermann

IPC: C07K14/74 ,  A61K38/06 ,  C07K16/30 ,  A61K38/17 ,  A61K39/00 ,  A61K45/06 ,  G01N33/569 ,  C12N5/0783 ,  C12N9/64 ,  G01N33/50 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  G01N33/566 ,  C12Q1/6886 ,  A61K38/08 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190022201A1

公开(公告)日：2019-01-24

申请号：US16065681

申请日：2016-11-29

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Helen HOERZER ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20190000947A1

公开(公告)日：2019-01-03

申请号：US16134422

申请日：2018-09-18

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Toni WEINSCHENK ,  Andrea MAHR ,  Jens FRITSCHE ,  Phillip MÜLLER ,  Anita WIEBE ,  Sara KUTSCHER

IPC: A61K39/00 ,  G01N33/68 ,  C07K14/725 ,  A61K38/04 ,  C07K7/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/435 ,  A61K35/17 ,  C12N15/115 ,  C12N5/0783 ,  C07K16/18 ,  C07K14/74 ,  A61K35/12

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells.

公开(公告)号：US20180282393A1

公开(公告)日：2018-10-04

申请号：US16009301

申请日：2018-06-15

Applicant: immatics biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/74 ,  C12Q1/6886 ,  A61K39/00 ,  C07K14/47 ,  C07K14/635 ,  C07K14/725 ,  C12N5/0783 ,  G01N33/574 ,  C07K16/28 ,  A61K38/00

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K39/00 ,  A61K39/0011 ,  C07K14/4748 ,  C07K14/635 ,  C07K14/7051 ,  C07K16/2833 ,  C07K2319/70 ,  C12N5/0638 ,  C12Q1/6886 ,  C12Q2600/156 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N33/57484

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180258155A1

公开(公告)日：2018-09-13

申请号：US15976621

申请日：2018-05-10

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K38/08 ,  C07K16/30 ,  A61K39/00 ,  A61K45/06 ,  C12N5/0783 ,  C12N9/64 ,  G01N33/50 ,  G01N33/566 ,  C07K7/02 ,  C07K7/06 ,  C07K14/00 ,  C07K14/47 ,  C07K14/725 ,  C07K16/18 ,  C07K16/28 ,  A61K38/06 ,  G01N33/569 ,  C12Q1/6886 ,  A61K38/17

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180258150A1

公开(公告)日：2018-09-13

申请号：US15979012

申请日：2018-05-14

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Oliver SCHOOR ,  Andrea MAHR ,  Toni WEINSCHENK ,  Anita WIEBE ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: C07K14/47 ,  A61K39/00 ,  C07K16/30 ,  C07K14/74 ,  C07K16/28 ,  C12N5/0783 ,  C07K14/725 ,  C12N15/113

CPC classification number: C07K14/4748 ,  A61K39/0011 ,  A61K39/001154 ,  A61K2039/5154 ,  A61K2039/5158 ,  A61P35/00 ,  C07K14/7051 ,  C07K14/70539 ,  C07K16/2833 ,  C07K16/3046 ,  C07K16/3076 ,  C07K2317/34 ,  C12N5/0636 ,  C12N15/1138 ,  C12N2310/16 ,  C12N2501/50

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T-cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180250374A1

公开(公告)日：2018-09-06

申请号：US15982500

申请日：2018-05-17

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C12N15/115 ,  C07K16/28

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20180237494A1

公开(公告)日：2018-08-23

申请号：US15956641

申请日：2018-04-18

Applicant: IMMATICS BIOTECHNOLOGIES GMBH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH ,  Lea STEVERMANN

IPC: C07K14/74 ,  A61K38/08 ,  G01N33/569 ,  G01N33/566 ,  C07K16/28 ,  C07K7/02 ,  C07K14/47 ,  C07K16/30 ,  C12N5/0783 ,  C07K16/18 ,  C07K7/06 ,  A61K39/00 ,  C12Q1/6886 ,  C12N9/64 ,  A61K45/06 ,  C07K14/725

CPC classification number: C07K14/70539 ,  A61K38/00 ,  A61K38/06 ,  A61K38/08 ,  A61K38/1774 ,  A61K39/0005 ,  A61K39/0011 ,  A61K45/06 ,  A61K2039/5158 ,  A61K2039/54 ,  A61K2039/57 ,  A61K2039/572 ,  A61K2039/585 ,  C07K7/02 ,  C07K7/06 ,  C07K14/001 ,  C07K14/47 ,  C07K14/4702 ,  C07K14/4748 ,  C07K14/7051 ,  C07K16/18 ,  C07K16/2833 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2319/00 ,  C07K2319/40 ,  C12N5/0636 ,  C12N5/0638 ,  C12N9/6491 ,  C12N2501/998 ,  C12N2502/11 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Y304/24 ,  G01N33/505 ,  G01N33/5088 ,  G01N33/566 ,  G01N33/56972 ,  G01N33/56977 ,  G01N2333/47 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70539 ,  G01N2500/10

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.